COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more
Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January. Ruffieux was head of global pharma technical operations at Roche (SIX:ROG; OTCQX:RHHBY). In April, Lonza agreed to manufacture an mRNA-based COVID-19 vaccine from Moderna Inc. (NASDAQ:MRNA), which also made a new addition to its C-suite this week. David Meline was hired as CFO, succeeding long-time CFO Lorence Kim, who plans to depart in August. Meline was CFO and EVP of Amgen Inc. (NASDAQ:AMGN) in 2014-19 (see "Lonza to Manufacture COVID-19 Vaccine").
Pfizer Inc. (NYSE:PFE) veteran Michael White joined cancer company Samumed LLC as CSO. He was CSO for tumor biology at the pharma. ...